SAN FRANCISCO, CA—Attendees of Heart Rhythm 2022 heard results from numerous studies investigating the impact of conduction-system pacing, which includes both His-bundle and left bundle branch (LBB) ...
NEW ORLEANS -- Among patients with heart failure, conduction system pacing-guided cardiac resynchronization therapy was associated with improvements in left ventricular ejection fraction (LVEF) ...
BIOTRONIK today announced the launch of the new Acticor Sky and Rivacor Sky device family featuring the world's first CE-approved left bundle branch area pacing (LBBAP) high-voltage device. These next ...
The European Society of Cardiology (ESC) has released a groundbreaking consensus statement on conduction system pacing (CSP), marking a significant milestone in the evolution of pacing therapy. The ...
Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates Medtronic is the first and only ...
Could single-lead pacing systems for the delivery of cardiac resynchronization therapy (CRT) match or even surpass systems with three leads? Perhaps, suggest several new comparative studies, including ...
The European Society of Cardiology (ESC) has released a groundbreaking consensus statement on conduction system pacing (CSP), marking a significant milestone in the evolution of pacing therapy. The ...
Please provide your email address to receive an email when new articles are posted on . Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area ...
Conduction system pacing (CSP) produced the same degree of cardiac resynchronization, ventricular reverse modeling, and similar clinical outcomes as did biventricular pacing (BiVP) in patients with ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...
MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the indication for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results